Quarterly ResultMay 12, 2026, 04:24 PM
iBio Q3 Net Loss $(7.73)M; Cash & Investments $74.8M
AI Summary
iBio reported a net loss of $(7.73) million for the three months ended March 31, 2026, and $(22.44) million for the nine months ended March 31, 2026. Despite increased operating expenses, the company significantly improved its liquidity position, ending the period with $47.63 million in cash and cash equivalents and $27.17 million in investments in debt securities, totaling $74.8 million. This enhanced financial standing, bolstered by recent equity raises and warrant exercises, is expected to fund operations for at least the next 12 months, addressing prior going concern doubts. The company also anticipates IBIO-600 to enter Phase 1a clinical trials in Q2 2026 and IBIO-610 in H1 2027.
Key Highlights
- Net loss for Q3 2026 was $(7.73) million, compared to $(4.86) million in Q3 2025.
- Net loss for the nine months ended March 31, 2026, was $(22.44) million.
- Cash and cash equivalents increased to $47.63 million as of March 31, 2026.
- Total current assets reached $77.25 million, including $27.17 million in debt securities.
- Net cash provided by financing activities was $83.64 million for the nine months.
- Research and development expenses for the nine months increased to $11.08 million.
- IBIO-600 is expected to enter Phase 1a clinical trials in Q2 calendar 2026.
- IBIO-610 is anticipated to commence human clinical trials in H1 calendar 2027.
Price Impact
More from IBIO